If you’ve been diagnosed with pancreatic cancer and your doctor has recommended chemotherapy, you may be hearing about two main regimens: FOLFIRINOX and gemcitabine plus nab-paclitaxel (Abraxane). Both are standard-of-care options, but they differ in important ways. Understanding these differences can help you have a more informed conversation with your oncologist.
What Is FOLFIRINOX?
FOLFIRINOX is a combination of four chemotherapy drugs:
- Folinic acid (leucovorin) — enhances the effect of fluorouracil
- Fluorouracil (5-FU) — interferes with cancer cell DNA
- Irinotecan — blocks an enzyme cancer cells need to divide
- Oxaliplatin — damages cancer cell DNA
FOLFIRINOX is typically given every two weeks through an IV infusion, with a take-home pump that delivers 5-FU over 46 hours. Clinical trials have shown strong response rates, but the combination can cause more side effects.
What Is Gemcitabine + Nab-Paclitaxel?
This two-drug combination pairs gemcitabine (a chemotherapy drug that has been a backbone of pancreatic cancer treatment for decades) with nab-paclitaxel (Abraxane), a protein-bound form of paclitaxel designed to deliver the drug more effectively to tumors. It is typically given weekly for three weeks, followed by a week off.
How Do They Compare?
| Factor | FOLFIRINOX | Gem + Nab-Paclitaxel |
|---|---|---|
| Number of drugs | 4 | 2 |
| Infusion schedule | Every 2 weeks + 46-hr pump | Weekly × 3, then 1 week off |
| Common side effects | Fatigue, nausea, diarrhea, neuropathy, low blood counts | Fatigue, nausea, hair loss, neuropathy, low blood counts |
| Side effect intensity | Generally higher | Generally more manageable |
| Who it’s typically for | Patients with good performance status (fit enough for aggressive treatment) | Broader range of patients |
A modified version of FOLFIRINOX (called mFOLFIRINOX) uses lower doses to reduce side effects while maintaining effectiveness. Ask your oncologist which version they recommend.
The Bottom Line
Neither regimen is universally “better” — the right choice depends on your overall health, the stage of your cancer, your biomarker results, and your personal preferences about treatment intensity and quality of life. Your oncologist can help you weigh these factors.
Reviewed by the XpertPatient Medical Team. Sources: NCCN Guidelines, PRODIGE 4/ACCORD 11 trial, MPACT trial.
